A new study makes a strong case for the importance of government support for basic research: Federally funded studies contributed to the science that underlies every one of the 210 new drugs approved between 2010 and 2016.

Researchers at Bentley University scoured millions of research papers for mentions of those 210 new molecular entities, or NMEs, as well as studies on their molecular targets. Then, they looked to see which of those studies had received any funding from the National Institutes of Health.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • If so much tax support is given 4 research, why are the Pharmaceutical companies allowed to proffit from this research and then turn around and make the taxpayer pay dearly for these drugs. Is there any Motion in the government 2 mediate this rip off

  • Good article Megan. I would be interested in a follow-up story on the 210 new drugs including what pharma co. used the taxpayer-funded research to develop new therapeutic for what conditions; what was the $ value of the tax-payer research, what patent protection did they received and what price did they establish for the new drugs. I would also be interested in learning where academic or medical institutions and/or their researchers personally benefited from selling the tax-payer research. And, learning if tax funded research grants include a return on equity provisions that allow for the reinvestment of capital obtained from successful research into funding more research grants. Thanks for your consideration.
    Jim

  • The NIH is a national treasure. Academia is the major beneficiary, and rightly so.
    The primary incentive in academia is “productivity”,still largely meaning publications.
    The commercial realm operates with different incentives, obviously.
    And obviously, there are egregious pricing schemes which are shameful ( think EpiPen).
    It’s messy, but only in theory is academia good at commercialization. Drug companies aren’t inclined toward nor are they typically geared toward fundamental research.
    Would more of one and less of the other be an improvement? There are way too many variables for me to even think of guessing.

  • Two questions that seem appropriate are:
    1) Other than the existence and use of the drugs for citizens, did the federal government receive anything in return for this investment (such as the return if the initial investment)?
    2) Was the investment in such drugs the result of any advocacy on Capitol Hill or within the the agency level and by whom?

    • The federal government received billions in tax revenue from the pharmaceutical industry and those employed by that industry.

      Typically, a decision by NIH to fund or not fund a specific project is not driven by advocacy on Capitol Hill or external groups acting on NIH. Of course, the overall NIH budget is subject to innumerable political pressures.

  • What was the mantra?
    High prices are necessary for drug innovation brought to you by private companies.
    More like, socialist research is

    • …and what does the public receive for its investment in basic research that leads to breakthrough drugs? Unaffordable drugs produced by the financialized pharmaceutical industry and the medical-industrial complex.

    • What does the public receive for its investment in basic research that leads to breakthrough drugs? The public gets to live longer, healthier lives! For example, age-adjusted death rates for heart disease fell from 520.4 deaths per 100,000 Americans in 1969 to 169.1 in 2013. Stroke deaths dropped from 156.8 per 100,000 Americans to 36. Much of this decrease is due to improved pharmacotherapy for high blood pressure, cholesterol and excessive clotting. I, like many Americans, take generic prescription medications to keep my blood pressure and cholesterol in check. Yes, many branded prescription medications are expensive. But, eventually the patent protections expire and these drugs typically get cheaper. In my case, my insurer has decided it is cheaper to give me generic prescription drugs for free than to pay for my hospitalization in the case of a heart attack or stroke

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy